After CSF1R and CCR2 antagonism, they confirmed a significant reduction in tumor infiltrating monocytes and macrophages and found that tumor size decreased, an enhanced response to chemotherapy, and that hepatic and peritoneal metastasis decreased (23). The gene discussed is CCR2; the disease is neoplasm.